Nurix Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nurix Therapeutics, Inc. on May 16, 2022, covering events occurring on May 15, 2022. The company is a Delaware corporation with its principal executive offices in San Francisco, California, and its common stock trades on the Nasdaq Global Market under the symbol NRIX.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the resignation of Clay B. Siegall, Ph.D. Effective immediately on May 15, 2022, Dr. Siegall resigned from the following positions:
- Class II member of the Board of Directors
- Member of the Compensation Committee
- Member of the Development Advisory Committee
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is limited to the notification of the director's departure.
Key Facts for Investor Verification
- Verify the effective date of Dr. Siegall's resignation (May 15, 2022).
- Confirm the specific committees from which Dr. Siegall stepped down (Compensation and Development Advisory).
- Check for subsequent filings regarding the appointment of a replacement director.
- Review the company's most recent 10-K or 10-Q for current financial status, as this 8-K contains no financial data.